美生物安全法案向前推进，被批 “狭隘的保护主义行为”，药明回应

JIN10
2024.03.07 02:05
3 月 6 日，美国参议院国土安全委员会投票通过一项法案，该法案可能以国家安全为由限制与华大基因和药明康德等中国生物科技公司的业务往来。药明康德周三在一份电子邮件声明中表示，该公司不收集基因数据，该法案 “依靠误导性指控和不准确的断言，在未经正当程序的情况下对我们公司提出先发制人和不合理的禁令”。
Source: JIN10 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.